|

Doxorubicin, Cisplatin, Methotrexate Clinical Trials

1 actively recruiting trial

Also known as: MAP

Pipeline

Phase 2/3: 1

Top Sponsors

  • Blokhin's Russian Cancer Research Center1

Indications

  • Neoplasms, Connective and Soft Tissue1
  • Neoplasms, Connective Tissue1
  • Sarcoma of Bone1
  • Sarcoma1
  • Osteosarcoma1

Other1 trial

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.